Alector, Inc. (0Z2.F)

4,8600 0,0000 (0,00%) Börsenschluss: 08:01AM CEST

Alector, Inc.

131 Oyster Point Boulevard
Suite 600
South San Francisco, CA 94080
United States
415 231 5660
https://www.alector.com

Sektor(en): 
Branche: 
Vollzeitmitarbeiter: 244

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Arnon Rosenthal Ph.D.	Co-Founder, CEO & Director	993,19k	N/A	1956
Dr. Marc Grasso M.D.	CFO, Principal Financial Officer & Principal Accounting Officer	680,07k	N/A	1974
Dr. Gary Romano M.D., Ph.D.	Chief Medical Officer	701,96k	N/A	1962
Mr. Peter Heutink Ph.D.	Chief Scientific Officer	N/A	N/A	N/A
Katie Hogan	Senior Director of Corporate Communication & Investor Relations	N/A	N/A	N/A
Ms. Danielle Pasqualone J.D., Ph.D.	General Counsel	N/A	N/A	N/A
Ms. Clare Hunt M.B.A.	Chief People Officer	N/A	N/A	N/A
Ms. Kristina Cutter M.P.H.	Chief Regulatory, Pharmacovigilance, & Quality Assurance Officer	N/A	N/A	N/A
Ms. Virginia DeJesus-Rueff M.B.A.	Chief of Staff & Head of Strategy	N/A	N/A	N/A
Ms. Norah Conway	Senior Vice President of Portfolio & Program Management	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

Corporate Governance

Alector, Inc.s ISS Governance QualityScore, Stand 29. April 2024, lautet 7. Die grundlegenden Scores sind Audit: 9, Vorstand: 5, Shareholderrechte: 8, Kompensation: 7.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.